Piecing Together the Pricing Puzzle: The Midterm Elections

There is no magic bullet that will dramatically impact drug pricing to everybody s liking patients, industry, and government. But a stepwise approach involving a series of changes, including taking advantage of the next midterm elections, could point the path toward a solution Powered by WPeMatico Continue reading Piecing Together the Pricing Puzzle: The Midterm Elections

More New Drugs and Generics Reshape Pharma Markets

Amidst all the outrage over surging pharma prices, the continued growth in generic drug prescribing has moderated overall spending on medicines, cooling the political heat on industry. Generics now account for nearly 90% of prescription drug use in the US due to policies facilitating their devel Powered by WPeMatico Continue reading More New Drugs and Generics Reshape Pharma Markets

Can Streamlined R&D Reduce Drug Prices?

The recent FDA approval of the first chimeric antigen receptor T cell (CAR-T) therapy to treat young patients with a serious form of leukemia reignited charges that high drug prices limit patient access to life-saving medicines. Novartis announced that it would charge $475,000 for treatment with Powered by WPeMatico Continue reading Can Streamlined R&D Reduce Drug Prices?

FDA, Manufacturers Strive to Prevent Drug Shortages from Hurricane Maria

The extensive volume of pharmaceutical manufacturing in Puerto Rico is driving FDA efforts to quickly assess facility damage and logistical problems to ensure continued supply of critical medicines. More than 20 companies, including Pfizer, Eli Lilly, Johnson & Johnson and Amgen, operate mor Powered by WPeMatico Continue reading FDA, Manufacturers Strive to Prevent Drug Shortages from Hurricane Maria